Renal function is a major predictor of circulating acyl-CoA-binding protein/diazepam-binding inhibitor

Area of Science:

• Endocrinology
• Nephrology
• Metabolic Research

Background:

• Acyl-CoA-binding protein (ACBP) is an endocrine factor influencing food intake and lipid metabolism.
• ACBP levels are dysregulated in catabolic states like sepsis and systemic inflammation.
• ACBP regulation in impaired kidney function remains uninvestigated.

Purpose of the Study:

• To investigate serum ACBP concentrations in individuals with kidney failure (KF) and acute kidney dysfunction (AKD).
• To explore the relationship between ACBP and estimated glomerular filtration rate (eGFR).
• To assess ACBP mRNA expression in chronic kidney disease (CKD) mouse models and in vitro adipocyte models.

Main Methods:

• Serum ACBP measured by ELISA in 60 KF patients on hemodialysis and 60 controls.
• ACBP levels assessed in a human AKD model.
• mACBP mRNA expression analyzed in CKD mouse tissues and indoxyl sulfate-exposed mouse adipocytes.

Main Results:

• Serum ACBP was ~20-fold higher in KF patients compared to controls (p<0.001).
• eGFR was the strongest inverse predictor of serum ACBP (β=-0.839; p<0.001).
• AKD increased ACBP concentrations nearly 3-fold (p<0.001); elevated ACBP was not due to increased mRNA expression.

Conclusions:

• Circulating ACBP is inversely associated with renal function, likely due to renal retention.
• Further research is needed on ACBP in malnutrition-related diseases like CKD.
• Future studies should consider renal function markers when investigating ACBP.